Efficacy of Pneumococcal Nontypable Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial

English version České info

Background:
The relationship between pneumococcal conjugate vaccine–induced antibody responses and protection against community-acquired pneumonia (CAP) and acute otitis media (AOM) is unclear. This study assessed the impact of the ten-valent pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on these end points. The primary objective was to demonstrate vaccine efficacy (VE) in a per-protocol analysis against likely bacterial CAP (B-CAP: radiologically confirmed CAP with alveolar consolidation/pleural effusion on chest X-ray, or non-alveolar infiltrates and C-reactive protein ≥ 40 µg/ml); other protocol-specified outcomes were also assessed.

Methods and Findings:
This phase III double-blind randomized controlled study was conducted between 28 June 2007 and 28 July 2011 in Argentine, Panamanian, and Colombian populations with good access to health care. Approximately 24,000 infants received PHiD-CV or hepatitis control vaccine (hepatitis B for primary vaccination, hepatitis A at booster) at 2, 4, 6, and 15–18 mo of age. Interim analysis of the primary end point was planned when 535 first B-CAP episodes, occurring ≥2 wk after dose 3, were identified in the per-protocol cohort. After a mean follow-up of 23 mo (PHiD-CV, n = 10,295; control, n = 10,201), per-protocol VE was 22.0% (95% CI: 7.7, 34.2; one-sided p = 0.002) against B-CAP (conclusive for primary objective) and 25.7% (95% CI: 8.4%, 39.6%) against World Health Organization–defined consolidated CAP. Intent-to-treat VE was 18.2% (95% CI: 5.5%, 29.1%) against B-CAP and 23.4% (95% CI: 8.8%, 35.7%) against consolidated CAP. End-of-study per-protocol analyses were performed after a mean follow-up of 28–30 mo for CAP and invasive pneumococcal disease (IPD) (PHiD-CV, n = 10,211; control, n = 10,140) and AOM (n = 3,010 and 2,979, respectively). Per-protocol VE was 16.1% (95% CI: −1.1%, 30.4%; one-sided p = 0.032) against clinically confirmed AOM, 67.1% (95% CI: 17.0%, 86.9%) against vaccine serotype clinically confirmed AOM, 100% (95% CI: 74.3%, 100%) against vaccine serotype IPD, and 65.0% (95% CI: 11.1%, 86.2%) against any IPD. Results were consistent between intent-to-treat and per-protocol analyses. Serious adverse events were reported for 21.5% (95% CI: 20.7%, 22.2%) and 22.6% (95% CI: 21.9%, 23.4%) of PHiD-CV and control recipients, respectively. There were 19 deaths (n = 11,798; 0.16%) in the PHiD-CV group and 26 deaths (n = 11,799; 0.22%) in the control group. A significant study limitation was the lower than expected number of captured AOM cases.

Conclusions:
Efficacy was demonstrated against a broad range of pneumococcal diseases commonly encountered in young children in clinical practice.

Trial registration:
www.ClinicalTrials.gov NCT00466947

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Efficacy of Pneumococcal Nontypable Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial. PLoS Med 11(6): e32767. doi:10.1371/journal.pmed.1001657
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001657

Souhrn

Conclusions:
Efficacy was demonstrated against a broad range of pneumococcal diseases commonly encountered in young children in clinical practice.

Trial registration:
www.ClinicalTrials.gov NCT00466947

Please see later in the article for the Editors' Summary

Zdroje

1. BlackRE, CousensS, JohnsonHL, LawnJE, RudanI, et al. (2010) Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375: 1969–1987 doi:10.1016/S0140-6736(10)60549-1

2. World Health Organization (2012) Pneumococcal vaccines WHO position paper—2012. Wkly Epidemiol Rec 87: 129–144.

3. O'BrienKL, WolfsonLJ, WattJP, HenkleE, Deloria-KnollM, et al. (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374: 893–902 doi:10.1016/S0140-6736(09)61204-6

4. JohnsonHL, Deloria-KnollM, LevineOS, StoszekSK, FreimanisHL, et al. (2010) Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 7: e1000348 doi:10.1371/journal.pmed.1000348

5. BardachA, CiapponiA, Garcia-MartiS, GlujovskyD, MazzoniA, et al. (2011) Epidemiology of acute otitis media in children of Latin America and the Caribbean: a systematic review and meta-analysis. Int J Pediatr Otorhinolaryngol 75: 1062–1070 doi:10.1016/j.ijporl.2011.05.014

6. PrymulaR, SchuermanL (2009) 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines 8: 1479–1500 doi:10.1586/erv.09.113

7. World Health Organization (2005) Pneumococcal conjugate vaccines. Recommendations for production and control of pneumococcal conjugate vaccines. WHO Tech Rep Ser 927 (Annex 2): 64–98.

8. LoensK, VanHL, Malhotra-KumarS, GoossensH, IevenM (2009) Optimal sampling sites and methods for detection of pathogens possibly causing community-acquired lower respiratory tract infections. J Clin Microbiol 47: 21–31 doi:10.1128/JCM.02037-08

9. GentileA, BardachA, CiapponiA, Garcia-MartiS, ArujP, et al. (2012) Epidemiology of community-acquired pneumonia in children of Latin America and the Caribbean: a systematic review and meta-analysis. Int J Infect Dis 16: e5–e15 doi:10.1016/j.ijid.2011.09.013

10. GentileA, BazanV (2011) Prevention of pneumococcal disease through vaccination. Vaccine 29 (Suppl 3)C15–C25 doi:10.1016/j.vaccine.2011.07.121

11. LagosR, MunozA, SanMO, MaldonadoA, HormazabalJC, et al. (2008) Age- and serotype-specific pediatric invasive pneumococcal disease: insights from systematic surveillance in Santiago, Chile, 1994–2007. J Infect Dis 198: 1809–1817 doi:10.1086/593334

12. PirezMC, AlgortaG, CedresA, SobreroH, VarelaA, et al. (2011) Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay. Pediatr Infect Dis J 30: 669–674 doi:10.1097/INF.0b013e3182152bf1

13. O'BrienKL (2013) PCV13 impact evaluations: the obvious and the unpredicted. Pediatr Infect Dis J 32: 264–265 doi:10.1097/INF.0b013e3182787f89

14. TaylorS, MarchisioP, VergisonA, HarriagueJ, HausdorffWP, et al. (2012) Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis 54: 1765–1773 doi:10.1093/cid/cis292

15. CastañedaE, AgudeloCI, RegueiraM, CorsoA, BrandileoneMC, et al. (2009) Laboratory-based surveillance of Streptococcus pneumoniae invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000–2005. Pediatr Infect Dis J 28: e265–e270 doi:10.1097/INF.0b013e3181a74b22

16. TregnaghiM, CeballosA, RuttimannR, UssherJ, TregnaghiP, et al. (2006) Active epidemiologic surveillance of pneumonia and invasive pneumococcal disease in ambulatory and hospitalized infants in Cordoba, Argentina. Pediatr Infect Dis J 25: 370–372 doi:10.1097/01.inf.0000208368.67448.51

17. ArguedasA, SherL, LopezE, Sáez-LlorensX, HamedK, et al. (2003) Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure. Pediatr Infect Dis J 22: 949–956 doi:10.1097/01.inf.0000095193.42502.d1

18. Sáez-LlorensX, RodriguezA, ArguedasA, HamedKA, YangJ, et al. (2005) Randomized, investigator-blinded, multicenter study of gatifloxacin versus amoxicillin/clavulanate treatment of recurrent and nonresponsive otitis media in children. Pediatr Infect Dis J 24: 293–300.

19. PichicheroME, ArguedasA, DaganR, SherL, Sáez-LlorensX, et al. (2005) Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure. Clin Infect Dis 41: 470–478 doi:10.1086/431584

20. RubinoCM, AmbroseP, CirincioneB, ArguedasA, SherL, et al. (2007) Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development. Diagn Microbiol Infect Dis 59: 67–74 doi:10.1016/j.diagmicrobio.2007.04.015

21. World Health Organization (2013) WHO vaccine-preventable diseases: monitoring system. 2013 global summary [database]. Available: http://apps.who.int/immunization_monitoring/globalsummary. Accessed 14 April 2013.

22. Ropero-AlvarezAM, KurtisHJ, Danovaro-HollidayMC, Ruiz-MatusC, AndrusJK (2009) Expansion of seasonal influenza vaccination in the Americas. BMC Public Health 9: 361 doi:10.1186/1471-2458-9-361

23. GiglioN, GentileA, LeesL, MiconeP, ArmoniJ, et al. (2012) Public health and economic benefits of new pediatric influenza vaccination programs in Argentina. Hum Vaccin Immunother 8: 312–322 doi:10.4161/hv.18569

24. The World Bank (2013) Data: countries and economies [database]. Available: http://data.worldbank.org/country. Accessed 16 April 2013.

25. World Health Organization (2013) Global health observatory data repository [database]. Available: http://apps.who.int/gho/data/node.main. Accessed 16 April 2013.

26. World Health Organization (2013) Global Health Observatory: infant mortality–situation and trends [database]. Available: http://www.who.int/gho/child_health/mortality/neonatal_infant_text/en/index.html. Accessed 16 April 2013.

27. Eurostat (2012 October) Mortality and life expectancy statistics. Available: http://epp.eurostat.ec.europa.eu/statistics_explained/index.php/Mortality_and_life_expectancy_statistics. Accessed 16 April 2013.

28. Mulholland K (2004) Ethical considerations arising from vaccine trials conducted in paediatric populations with high disease burden in developing countries. WHO/V&B/04.04. Geneva: World Health Organization.

29. World Health Organization Pneumonia Vaccine Trial Investigators' Group (2001) Standardization of interpretation of chest radiographs for the diagnosis of pneumonia in children. WHO/V&B/01.35. Geneva: World Health Organization.

30. MadhiSA, KlugmanKP (2007) World Health Organisation definition of “radiologically-confirmed pneumonia” may under-estimate the true public health value of conjugate pneumococcal vaccines. Vaccine 25: 2413–2419 doi:10.1016/j.vaccine.2006.09.010

31. FriedmanNR, McCormickDP, PittmanC, ChonmaitreeT, TeichgraeberDC, et al. (2006) Development of a practical tool for assessing the severity of acute otitis media. Pediatr Infect Dis J 25: 101–107 doi:10.1097/01.inf.0000199290.73333.89

32. DaganR, LeibovitzE, GreenbergD, YagupskyP, FlissDM, et al. (1998) Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatr Infect Dis J 17: 776–782.

33. GoldsteinB, GiroirB, RandolphA (2005) International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 6: 2–8.

34. ConcepcionNF, FraschCE (2001) Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 8: 266–272.

35. HenckaertsI, GoldblattD, AshtonL, PoolmanJ (2006) Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 13: 356–360.

36. PoolmanJT, FraschCE, KayhtyH, LestrateP, MadhiSA, et al. (2010) Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol 17: 134–142 doi:10.1128/CVI.00289-09

37. Romero-SteinerS, LibuttiD, PaisLB, DykesJ, AndersonP, et al. (1997) Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 4: 415–422.

38. HenckaertsI, DurantN, De GraveD, SchuermanL, PoolmanJ (2007) Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 25: 2518–2527.

39. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1998) ICH Topic E9. Statistical principles for clinical trials. CPMP/ICH/363/96. London: European Medicines Agency.

40. European Medicines Agency (2008) Ethical considerations for clinical trials on medicinal products conducted with the paediatric population. London: European Medicines Agency.

41. BlackSB, ShinefieldHR, LingS, HansenJ, FiremanB, et al. (2002) Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21: 810–815 doi:10.1097/01.inf.0000027926.99356.4c

42. CuttsFT, ZamanSM, EnwereG, JaffarS, LevineOS, et al. (2005) Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365: 1139–1146 doi:10.1016/S0140-6736(05)71876-6

43. KlugmanKP, MadhiSA, HuebnerRE, KohbergerR, MbelleN, et al. (2003) A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349: 1341–1348.

44. LuceroMG, NohynekH, WilliamsG, TalloV, SimoesEA, et al. (2009) Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Pediatr Infect Dis J 28: 455–462 doi:10.1097/INF.0b013e31819637af

45. HansenJ, BlackS, ShinefieldH, CherianT, BensonJ, et al. (2006) Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 25: 779–781 doi:10.1097/01.inf.0000232706.35674.2f

46. Guiñazù JR, Moreira M, Tregnaghi MW, Madhi SA, Hausdorff WP, et al. (2014) Effect of infant immunization on pneumonia with alveolar consolidation by age: comparison of double-blind randomized controlled trials [abstract]. 9th Biennial International Symposium on Pneumococci & Pneumococcal Diseases; 9–13 March 2014; Hyderabad, India.

47. MonastaL, RonfaniL, MarchettiF, MonticoM, VecchiBL, et al. (2012) Burden of disease caused by otitis media: systematic review and global estimates. PLoS ONE 7: e36226 doi:10.1371/journal.pone.0036226

48. PalmuA, JokinenJ, KilpiT (2008) Impact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine. Vaccine 26: 2466–2470 doi:10.1016/j.vaccine.2008.03.013

49. FletcherMA, FritzellB (2012) Pneumococcal conjugate vaccines and otitis media: an appraisal of the clinical trials. Int J Otolaryngol 2012: 312935 doi:10.1155/2012/312935

50. PrymulaR, PeetersP, ChrobokV, KrizP, NovakovaE, et al. (2006) Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367: 740–748.

51. RodgersGL, ArguedasA, CohenR, DaganR (2009) Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine 27: 3802–3810 doi:10.1016/j.vaccine.2009.04.021

52. JokinenJ, PalmuAA, KilpiT (2012) Acute otitis media replacement and recurrence in the Finnish otitis media vaccine trial. Clin Infect Dis 55: 1673–1676 doi:10.1093/cid/cis799

53. JansenAG, HakE, VeenhovenRH, DamoiseauxRA, SchilderAG, et al. (2009) Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database Syst Rev 2009: CD001480 doi:10.1002/14651858.CD001480.pub3

54. FiremanB, BlackSB, ShinefieldHR, LeeJ, LewisE, et al. (2003) Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 22: 10–16 doi:10.1097/01.inf.0000045221.96634.7c

55. PalmuAA, JokinenJ, BorysD, NieminenH, RuokokoskiE, et al. (2013) Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 382: 214–222 doi:10.1016/S0140-6736(12)61854-6

56. BlackS, ShinefieldH, FiremanB, LewisE, RayP, et al. (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19: 187–195.

57. FitzwaterSP, ChandranA, SantoshamM, JohnsonHL (2012) The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 31: 501–508 doi:10.1097/INF.0b013e31824de9f6

58. Sociedad Argentina de Pediatría (2012) Investigación en pediatría: posición de la Sociedad Argentina de Pediatría. Available: http://www.sap.org.ar/prof-comunicaciones12_investigacion.php. Accessed 29 April 2014.